Laboratory Products
Approval and Funding Granted for a Phase II Clinical Trial of Inecalcitol in Psoriasis
Jan 12 2012
Hybrigenics announced recently that AFSSAPS, the French drug agency, has granted authorisation for a Phase II clinical trial with oral inecalcitol in patients with moderate-to-severe psoriasis under an Investigational Medicinal Product Dossier (IMPD) procedure. Hybrigenics also announces it has received a zero interest loan of EUR 650,000 from OSEO, the French financial institution supporting innovation, to cover 45% of the overall costs of the study.
The study will be conducted by professor Jean-Paul Ortonne in the Dermatology Department of the University Hospital of Nice, France. It will be a double-blinded and placebocontrolled trial comparing inecalcitol in 40 patients vs. placebo
in 20 patients. Inecalcitol will be given orally at four milligrams per day for 16 weeks.
"We are delighted to investigate the full anti-proliferative potential of inecalcitol in psoriasis, a second indication in
addition to prostate cancer. This study could extend the therapeutic potential of inecalcitol to non-cancerous
proliferative diseases," said Dr Jean-François Dufour- Lamartinie, head of clinical R&D.
"We are also grateful to OSEO for its support to finance nearly half the cost of this Phase II trial. Oral treatment of moderate-tosevere psoriasis by inecalcitol would be a major breakthrough as compared with older oral drugs such as cyclosporin, methotrexate or retinoids which are immunosuppressant or teratogenic. The convenience of oral dministration of inecalcitol would also represent an alternative of choice to more recent but injectable biological treatments."
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 04 2024 Chiba, Tokyo, Japan
Sep 04 2024 University of Warwick, Coventry, UK
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 11 2024 Bangkok, Thailand